Capricor Therapeutics (CAPR) Stock Analysis

What Capricor Therapeutics does

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Key metrics

ETFs linked to CAPR

Broad-market and Healthcare sector ETFs an investor holding Capricor Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CAPR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Capricor Therapeutics?

Capricor Therapeutics trades under the ticker CAPR on NASDAQ.

Which exchange is CAPR listed on?

CAPR is listed on NASDAQ.

What sector does Capricor Therapeutics operate in?

Capricor Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CAPR in a portfolio?

PortView shows CAPR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.